<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung CancersKristin Bergethon, A. John Iafrate, Ryohei Katayama et al.|Journal of Clinical Oncology|2012Cited by 1.6k
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET AmplificationSai‐Hong Ignatius Ou, A. John Iafrate, Eunice L. Kwak et al.|Journal of Thoracic Oncology|2011Cited by 439